Volume 85 Issue 18 | p. 18 | Concentrates
Issue Date: April 30, 2007

Cytos licenses vaccine to Novartis

Department: Business

Cytos Biotechnology has licensed CYT002-NicQb, a therapeutic vaccine in Phase II development for the treatment of nicotine addiction, to fellow Swiss firm Novartis. Cytos will get close to $30 million up front from Novartis and could receive almost $500 million in various milestone payments. According to Cytos, vaccination with CYT002-NicQb has been shown to induce nicotine-specific antibodies that bind nicotine in the bloodstream.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment